

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

Control-FREEC

RRID:SCR_010822

Type: Tool

Proper Citation

Control-FREEC (RRID:SCR_010822)

Resource Information

URL: <http://bioinfo-out.curie.fr/projects/freec/tutorial.html>

Proper Citation: Control-FREEC (RRID:SCR_010822)

Description: Prediction of copy number alterations and loss of heterozygosity using deep-sequencing data.

Abbreviations: Control-FREEC

Resource Type: software resource

Resource Name: Control-FREEC

Resource ID: SCR_010822

Alternate IDs: OMICS_00344

Record Creation Time: 20220129T080300+0000

Record Last Update: 20260801T190416+0000

Ratings and Alerts

No rating or validation information has been found for Control-FREEC.

No alerts have been found for Control-FREEC.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 346 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Radulovich N, et al. (2026) Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report. *Cancer research communications*, 6(4), 832.

Morrissey RL, et al. (2026) Elucidating cooperative genetic events in DCIS progression in mutant p53-driven breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, 123(2), e2526544123.

Fernando W, et al. (2026) Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy. *Nature communications*, 17(1).

Sugawara M, et al. (2026) Establishment and genomic characterization of patient-derived organoids from gastric-type cervical adenocarcinoma. *Journal of gynecologic oncology*, 37(3), e101.

Ju H, et al. (2026) Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial. *Nature communications*, 17(1).

Nakamura Y, et al. (2026) Mutational profiles of spontaneous and radiation-related mammary carcinomas in a rat model of Brca1 haploinsufficiency. *Scientific reports*, 16(1).

Huang M, et al. (2026) Patient-derived organoids predict chemotherapy response of locally advanced gastric cancer. *PloS one*, 21(3), e0339416.

Liu Y, et al. (2026) HaploC-tools reveal haplotype-specific chromosome conformation and chromatin states. *Nature communications*, 17(1).

Castellacci M, et al. (2026) Exploring the genetic diversity of Mediterranean fig trees highlights genes associated with fruit traits. *Frontiers in plant science*, 17, 1750632.

Sada H, et al. (2026) Colon-Restricted Phosphatase and Tensin Homolog Deleted From Chromosome 10 Haploinsufficiency Models Phosphoinositide 3-Kinase Pathway-Driven Invasion in Colorectal Cancer. *Cellular and molecular gastroenterology and hepatology*, 20(9), 101773.

Bellomo SE, et al. (2026) Genome-wide biomarker analysis across the full spectrum of HER2-expressing breast cancers to reveal a clonal chromosome 17 imbalance defining unfavourable HER2-low disease. *Biomarker research*, 14(1).

Dong YP, et al. (2026) Early replication fragile sites are associated with cancer-related CNVs and SNVs in human embryonic stem cells. *Stem cell reports*, 21(7), 102968.

Schönbichler A, et al. (2026) Tyrosine kinase targeting uncovers oncogenic pathway plasticity in Tasmanian devil transmissible cancers. *The EMBO journal*, 45(5), 1426.

Andrieu C, et al. (2026) Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patients. *Oncogene*, 45(4), 549.

Yang W, et al. (2026) Is random biopsy necessary for normal esophageal mucosa during chromoendoscopy? Evidence from a population-based cohort study. *BMC medicine*, 24(1).

Sun L, et al. (2026) ADAR1p110 promotes hepatocellular carcinoma metastasis via the miR-451a/TUBA1A axis. *Genes & diseases*, 13(5), 101770.

Liu B, et al. (2026) Biomimetic 3D-Bioprinted organoids of thymic epithelial tumors for translational drug screening and biomarker identification. *Materials today. Bio*, 37, 102878.

Song F, et al. (2026) Patient-derived organotypic tumor spheroids as a functional platform for predicting immunotherapeutic responses and guiding precision treatment for hepatocellular carcinoma. *Journal for immunotherapy of cancer*, 14(5).

Mohammadi M, et al. (2025) Cyclin-dependent kinase 9 inhibitors as oncogene signaling modulators in combination with targeted therapy for the treatment of colorectal cancer. *bioRxiv : the preprint server for biology*.

Suzuki K, et al. (2025) Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF- β axis in adult T-cell leukemia/lymphoma. *Leukemia*, 39(10), 2465.